SABR COMET 3

Name No. For Patients with Purpose
SABR COMET 3 CTRIAL-IE 19-21

Oligometastatic disease who have one controlled primary solid tumour and 1-3 current metastatic lesions, and a maximum of 8 lifetime metastatic lesions

The purpose of the study is to assess the impact of Stereotactic Ablative Radiotherapy (SABR), compared to standard of care (SOC) treatment, on overall survival, oncologic outcomes, and quality of life in patients with 1-3 current metastatic lesions.


MK7339-002 / LYNK-002

Name No. For Patients with Purpose
MK7339-002 / LYNK-002 CTRIAL-IE 19-27

Multiple types of cancer

This study will evaluate the efficacy and safety of olaparib monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic).